Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03318939 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation
A Phase 2 study, sponsored by Spectrum Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 648
- Enrollment target
NCT03318939 is a Phase 2 study that was terminated before completion, run by Spectrum Pharmaceuticals. The registered enrollment target is 648 participants.
The verdict
NCT03318939, a Phase 2 study, was terminated before completion, sponsored by Spectrum Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 648 participants
- Enrollment target
Study Summary
This is a Phase 2, open-label, multi-center study to evaluate the efficacy and the safety/tolerability of poziotinib in seven participant cohorts for up to 603 previously treated and treatment-naïve NSCLC participant. Cohorts 3 and 4 were added with Amendment 1 and three additional cohorts were added with Amendment 2 (Cohorts 5, 6 and 7).
Interventions
- DRUG Poziotinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 648 participants |
| Start Date | 2017-10-11 |
| Est. Completion | 2023-04-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03318939
The ClinicalTrials.gov registry entry for NCT03318939 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 648 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Spectrum Pharmaceuticals, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Poziotinib is the first listed.
NCT03318939 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03318939 about?
NCT03318939 is a clinical study titled "Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation". This is a Phase 2, open-label, multi-center study to evaluate the efficacy and the safety/tolerability of poziotinib in seven participant cohorts for up to 603 previously treated and treatment-naïve NSCLC participant. Cohorts 3 and 4 were added with Amendment 1 and three additional cohorts were adde...
What is the current status of trial NCT03318939?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 648 participants. The study started on 2017-10-11. Estimated completion is 2023-04-03.
What interventions are being tested in trial NCT03318939?
The interventions under investigation include: Poziotinib (DRUG).
Who is sponsoring clinical trial NCT03318939?
This trial is sponsored by Spectrum Pharmaceuticals, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.